Shahid Shekhani, MD
Medical Oncology · Janesville, WINPI 1649278870
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.1%), education and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Seagen Inc. at 34.3% of the total. Reporting peaked in 2023 at $1,752 and has fallen 93.5% since, to $115 in 2025.
Across 41 payments — averaging $88.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$1K
- Exelixis Inc.$555
- EMD Serono, Inc.$528
- Sanofi$216
- Incyte Corporation$175
- Merck$128
- plus $788 from 15 others
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Consulting fees$1,75048%
- Speaking & faculty fees$2005%
- Food & beverage$68919%
- Education$1,00127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 1 | $1,250 |
| Exelixis Inc. | 6 | $555 |
| EMD Serono, Inc. | 3 | $528 |
| Sanofi | 2 | $216 |
| Incyte Corporation | 3 | $175 |
| Merck | 3 | $128 |
| Johnson & Johnson(2 entities) | 3 | $125 |
| AbbVie | 2 | $124 |
| Lilly USA, LLC | 1 | $101 |
| Amgen | 2 | $101 |
| AstraZeneca | 1 | $78 |
| Novartis | 3 | $51 |
| Pfizer | 2 | $38 |
| Taiho Oncology, Inc. | 1 | $31 |
| Genentech USA, Inc. | 2 | $30 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Bristol Myers Squibb | 1 | $18 |
| Verastem, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,640 in reported general payments places this provider in the 70th percentile of 54 medical oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 13 | $181,325 |
| VenclextaVenetoclax | 12 | $89,126 |
| Abiraterone Acetate | 37 | $82,380 |
| EliquisApixaban | 81 | $80,011 |
| XareltoRivaroxaban | 16 | $18,300 |
| Anastrozole | 178 | $3,782 |
| Exemestane | 13 | $3,509 |
| Letrozole | 126 | $2,750 |
| Fentanyl | 19 | $2,296 |
| Ondansetron Hcl | 133 | $2,088 |
| Dexamethasone | 99 | $1,919 |
| Hydroxyurea | 39 | $1,255 |
| Acyclovir | 55 | $1,182 |
| Oxycodone Hcl | 13 | $726 |
| Prednisone | 124 | $721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna | $51 | $181,32513 claims |
| AbbVieVenclexta | $124 | $89,12612 claims |
| PfizerEliquis | $38 | $80,01181 claims |
| Johnson & JohnsonXarelto | $125 | $18,30016 claims |
| Lilly USA, LLCOlanzapine | $101 | $10711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 54 medical oncology providers in Wisconsin.
Other medical oncology in Janesville
- Ismael ShaukatJanesville$45
- Alexandria PhanMilwaukee$260K
- Joshua LangMadison$114K
- Dustin DemingMadison$100K
- Kari WisinskiMadison$43K
- Hui-Zi ChenMilwaukee$41K
- Justine BruceMadison$25K
- Francis CuevasFranklin$14K
- Glenn LiuMadison$13K
- Toby CampbellMadison$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.